Michael Hemann: Difference between revisions
Content deleted Content added
No edit summary |
rm BLP sources, add BLP unsourced |
||
| Line 1: | Line 1: | ||
{{BLP |
{{BLP unsourced|date=June 2011}} |
||
'''Michael Thomas Hemann''', Ph.D. is a cancer geneticist and associate professor in the [[MIT Center for Cancer Research|David H. Koch Institute for Integrated Cancer Research]] at the [[Massachusetts Institute of Technology]]. |
'''Michael Thomas Hemann''', Ph.D. is a cancer geneticist and associate professor in the [[MIT Center for Cancer Research|David H. Koch Institute for Integrated Cancer Research]] at the [[Massachusetts Institute of Technology]]. |
||
Revision as of 21:35, 19 December 2012
 |
Michael Thomas Hemann, Ph.D. is a cancer geneticist and associate professor in the David H. Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology.
The research in Hemann's laboratory focuses on identification and characterization of genes involved in tumor formation, cancer progression, and chemotherapeutic response.
Michael was born in Ohio in 1971.
Publications
- Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT (2010). "Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy". Proc Natl Acad Sci U S A. 107 (48): 20786–91. doi:10.1073/pnas.1011409107. PMC 2996428. PMID 21068376.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Gilbert LA, Hemann MT (2010). "DNA damage-mediated induction of a chemoresistant niche". Cell. 143 (3): 355–66. doi:10.1016/j.cell.2010.09.043. PMC 2972353. PMID 21029859.
{{cite journal}}: Unknown parameter|month=ignored (help) - Doles J, Hemann MT (2010). "Nek4 status differentially alters sensitivity to distinct microtubule poisons". Cancer Res. 70 (3): 1033–41. doi:10.1158/0008-5472.CAN-09-2113. PMC 2946156. PMID 20103636.
{{cite journal}}: Unknown parameter|month=ignored (help) - Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT (2009). "In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression". Nat. Genet. 41 (10): 1133–7. doi:10.1038/ng.451. PMC 2756700. PMID 19783987.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT (2009). "The combined status of ATM and p53 link tumor development with therapeutic response". Genes Dev. 23 (16): 1895–909. doi:10.1101/gad.1815309. PMC 2725944. PMID 19608766.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)